Zomedica Corp.
Zomedica Corp. (ZOMDF): 4 pipeline candidates · 8 upcoming catalysts · ~14 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
14.0 months
D/E 0.10 · 0% dilution
Lead: Approved
4 candidates
8 upcoming, next in ~277d
12 buys · 0 sells (180d)
A transparent, data-derived signal for Zomedica Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$88.2M
Cash
$9.4M
Quarterly Burn
$5.3M
Runway
14.0 mo
Revenue
$8.8M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| celecoxib | Approved |
| diclofenac | Approved |
| pulsevet shock wave therapy | Preclinical |
| vetigel | Approved |
Upcoming Catalysts (8)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$11K
| Holder | Shares | Value |
|---|---|---|
| ancora advisors llc | 83,610 | $10K |
| corecap advisors, llc | 4,800 | $573 |
| gill capital partners, llc | 2,719 | $325 |
| harbour investments, inc. | 2,200 | $263 |
Frequently asked questions
How many drug candidates are in Zomedica Corp.'s pipeline?
Zomedica Corp. (ZOMDF) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Zomedica Corp.'s lead drug candidate?
Zomedica Corp.'s most advanced tracked candidate is celecoxib (Approved) for 1. INDICATIONS AND USAGE Celecoxib capsule are indicated Celecoxib capsules are nonsteroidal anti-inflammatory drug indicated for: • Osteoarthritis (OA) ( 1.1 ) • Rheumatoid Arthritis (RA) ( 1.2 ) • Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older ( 1.3 ) • Ankylosing Spondylitis (AS) ( 1.4 ) • Acute Pain (AP) ( 1.5 ) • Primary Dysmenorrhea (PD) ( 1.6 ) 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA [ see Clinical Studies (14.1) ]. 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA [ see Clinical Studies (14.2) ]. 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older [ see Clinical Studies (14.3) ]. 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS [ see Clinical Studies (14.4) ]. 1.5 Acute Pain For the management of acute pain in adults [ see Clinical Studies (14.5) ]. 1.6 Primary Dysmenorrhea For the management of primary dysmenorrhea [ see Clinical Studies (14.5) ]..
What is Zomedica Corp.'s next catalyst?
Zomedica Corp.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: DYLOJECT" — expected March 22, 2027.
What is Zomedica Corp.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Zomedica Corp. has approximately 14.0 months of cash runway.
What is Zomedica Corp.'s market capitalization?
Zomedica Corp.'s market capitalization is approximately $88.2M.
Get the full picture on Zomedica Corp.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.